References:
[1] Brown JS, Amend SR, Austin RH, Gatenby RA, Hammarlund EU, Pienta KJ. Updating the Definition of Cancer. Mol Cancer Res. 2023 Nov 1;21(11):1142-1147. doi: 10.1158/1541-7786.MCR-23-0411. PMID: 37409952; PMCID: PMC10618731.

[2] Piña-Sánchez P, Chávez-González A, Ruiz-Tachiquín M, Vadillo E, Monroy-García A, Montesinos JJ, Grajales R, Gutiérrez de la Barrera M, Mayani H. Cancer Biology, Epidemiology, and Treatment in the 21st Century: Current Status and Future Challenges From a Biomedical Perspective. Cancer Control. 2021 Jan-Dec; 28:10732748211038735. doi: 10.1177/10732748211038735. PMID: 34565215; PMCID: PMC8481752.

[3] Spagnolo F, Brugiapaglia S, Perin M, Intonti S, Curcio C. Anti-Cancer Drugs: Trends and Insights from PubMed Records. Pharmaceutics. 2025 May 4;17(5):610. doi: 10.3390/pharmaceutics17050610. PMID: 40430901; PMCID: PMC12115157.

[4] Morales-Cruz M, Delgado Y, Castillo B, Figueroa CM, Molina AM, Torres A, Milián M, Griebenow K. Smart Targeting To Improve Cancer Therapeutics. Drug Des Devel Ther. 2019 Oct 30;13:3753-3772. doi: 10.2147/DDDT.S219489. PMID: 31802849; PMCID: PMC6826196.

[5] Abujamous L, Soltani A, Al-Thawadi H, Agouni A. Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer. Biomol Biomed. 2024 Mar 11;24(2):230-237. doi: 10.17305/bb.2023.9757. PMID: 38231530; PMCID: PMC10950340.

[6] Wang B, Hu S, Teng Y, Chen J, Wang H, Xu Y, Wang K, Xu J, Cheng Y, Gao X. Current advance of nanotechnology in diagnosis and treatment for malignant tumors. Signal Transduct Target Ther. 2024 Aug 12;9(1):200. doi: 10.1038/s41392-024-01889-y. PMID: 39128942; PMCID: PMC11323968.

[7] Gavas S, Quazi S, Karpiński TM. Nanoparticles for Cancer Therapy: Current Progress and Challenges. Nanoscale Res Lett. 2021 Dec 5;16(1):173. doi: 10.1186/s11671-021-03628-6. PMID: 34866166; PMCID: PMC8645667.

[8] Joudeh N, Linke D. Nanoparticle classification, physicochemical properties, characterization, and applications: a comprehensive review for biologists. J Nanobiotechnology. 2022 Jun 7;20(1):262. doi: 10.1186/s12951-022-01477-8. PMID: 35672712; PMCID: PMC9171489.

[9] Giang I, Boland EL, Poon GM. Prodrug applications for targeted cancer therapy. AAPS J. 2014 Sep;16(5):899-913. doi: 10.1208/s12248-014-9638-z. Epub 2014 Jul 9. PMID: 25004822; PMCID: PMC4147050.

[10] Wang W, Fan J, Zhu G, Wang J, Qian Y, Li H, Ju J, Shan L. Targeted Prodrug-Based Self-Assembled Nanoparticles for Cancer Therapy. Int J Nanomedicine. 2020 Apr 24;15:2921-2933. doi: 10.2147/IJN.S247443. PMID: 32425524; PMCID: PMC7187935.

[11] Wu KM. A New Classification of Prodrugs: Regulatory Perspectives. Pharmaceuticals (Basel). 2009 Oct 14;2(3):77-81. doi: 10.3390/ph2030077. PMID: 27713225; PMCID: PMC3978533.

[12] Shah K, Gupta JK, Chauhan NS, Upmanyu N, Shrivastava SK, Mishra P. Prodrugs of NSAIDs: A Review. Open Med Chem J. 2017 Nov 30;11:146-195. doi: 10.2174/1874104501711010146. PMID: 29387273; PMCID: PMC5748882.

[13] Markovic M, Ben-Shabat S, Dahan A. Prodrugs for Improved Drug Delivery: Lessons Learned from Recently Developed and Marketed Products. Pharmaceutics. 2020 Oct 29;12(11):1031. doi: 10.3390/pharmaceutics12111031. PMID: 33137942; PMCID: PMC7692606.

[14] Tu Y, Gong J, Mou J, Jiang H, Zhao H, Gao J. Strategies for the development of stimuli-responsive small molecule prodrugs for cancer treatment. Front Pharmacol. 2024 Jul 31;15:1434137. doi: 10.3389/fphar.2024.1434137. PMID: 39144632; PMCID: PMC11322083.

[15] Mahato R, Tai W, Cheng K. Prodrugs for improving tumor targetability and efficiency. Adv Drug Deliv Rev. 2011 Jul 18;63(8):659-70. doi: 10.1016/j.addr.2011.02.002. Epub 2011 Feb 17. PMID: 21333700; PMCID: PMC3132824

[16] Wang H, Monroe M, Leslie F, Flexner C, Cui H. Supramolecular nanomedicines through rational design of self-assembling prodrugs. Trends Pharmacol Sci. 2022 Jun;43(6):510-521. doi: 10.1016/j.tips.2022.03.003. Epub 2022 Apr 19. PMID: 35459589; PMCID: PMC9106924.

[17] Chen KJ, Plaunt AJ, Leifer FG, Kang JY, Cipolla D. Recent advances in prodrug-based nanoparticle therapeutics. Eur J Pharm Biopharm. 2021 Aug;165:219-243. doi: 10.1016/j.ejpb.2021.04.025. Epub 2021 May 9. PMID: 33979661

[18] Junyaprasert VB, Thummarati P. Innovative Design of Targeted Nanoparticles: Polymer-Drug Conjugates for Enhanced Cancer Therapy. Pharmaceutics. 2023 Aug 27;15(9):2216. doi: 10.3390/pharmaceutics15092216. PMID: 37765185; PMCID: PMC10537251.

[19] Li G, Sun B, Li Y, Luo C, He Z, Sun J. Small-Molecule Prodrug Nanoassemblies: An Emerging Nanoplatform for Anticancer Drug Delivery. Small. 2021 Dec;17(52):e2101460. doi: 10.1002/smll.202101460. Epub 2021 Aug 3. PMID: 34342126.

[20] Wang J, Xu P, Zhang Y, Han S, Wang G, Wang H, Song H, Li S. Dynamic nanoassemblies derived from small-molecule homodimeric prodrugs for in situ drug activation and safe osteosarcoma treatment. iScience. 2023 Jul 17;26(8):107409. doi: 10.1016/j.isci.2023.107409. PMID: 37554455; PMCID: PMC10404730.

[21] Liu P, Huang Y, Zhan C, Zhang F, Deng C, Jia Y, Wan T, Wang S, Li B. Tumor-overexpressed enzyme responsive amphiphiles small molecular self-assembly nano-prodrug for the chemo-phototherapy against non-small-cell lung cancer. Mater Today Bio. 2023 Jul 4;21:100722. doi: 10.1016/j.mtbio.2023.100722. PMID: 37545562; PMCID: PMC10401344.

[22] Wang H, Lu Z, Wang L, Guo T, Wu J, Wan J, Zhou L, Li H, Li Z, Jiang D, Song P, Xie H, Zhou L, Xu X, Zheng S. New Generation Nanomedicines Constructed from Self-Assembling Small-Molecule Prodrugs Alleviate Cancer Drug Toxicity. Cancer Res. 2017 Dec 15;77(24):6963-6974. doi: 10.1158/0008-5472.CAN-17-0984. Epub 2017 Oct 20. PMID: 29055017.

[23] Xu P, Meng F, Wan J, Zhu H, Fang S, Wang H. Hybrid Homodimeric Prodrug Nanoassemblies for Low-Toxicity and Synergistic Chemophotodynamic Therapy of Melanoma. Biomater Res. 2024 Nov 1;28:0101. doi: 10.34133/bmr.0101. PMID: 39492977; PMCID: PMC11529783.

[24] Linlin Shi, a Shanshan Lin, Fengping Zhou,a Hao Jianga and Jin Zhang a.Recent advances in engineering prodrug- based nanomedicines for cancer therapy.Mater.Adv.2024,5,4634. Doi:DOI: 10.1039/d3ma01132a

[25] Zhang Y, Cui H, Zhang R, Zhang H, Huang W. Nanoparticulation of Prodrug into Medicines for Cancer Therapy. Adv Sci (Weinh). 2021 Sep;8(18):e2101454. doi: 10.1002/advs.202101454. Epub 2021 Jul 29. PMID: 34323373; PMCID: PMC8456229.

[26] Luo C, Sun J, Sun B, He Z. Prodrug-based nanoparticulate drug delivery strategies for cancer therapy. Trends Pharmacol Sci. 2014 Nov;35(11):556-66. doi: 10.1016/j.tips.2014.09.008. Epub 2014 Oct 16. PMID: 25441774.

[27] Cui T, Zhang S, Sun H. Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment. Oncol Rep. 2017 Feb;37(2):1253-1260. doi: 10.3892/or.2017.5345. Epub 2017 Jan 2. PMID: 28075466.

[28] Zhang Q, Kuang G, He S, Lu H, Cheng Y, Zhou D, Huang Y. Photoactivatable Prodrug-Backboned Polymeric Nanoparticles for Efficient Light-Controlled Gene Delivery and Synergistic Treatment of Platinum-Resistant Ovarian Cancer. Nano Lett. 2020 May 13;20(5):3039-3049. doi: 10.1021/acs.nanolett.9b04981. Epub 2020 Apr 9. PMID: 32250633.

[29] Xie A, Hanif S, Ouyang J, Tang Z, Kong N, Kim NY, Qi B, Patel D, Shi B, Tao W. Stimuli-responsive prodrug-based cancer nanomedicine. EBioMedicine. 2020 Jun;56:102821. doi: 10.1016/j.ebiom.2020.102821. Epub 2020 Jun 7. PMID: 32505922; PMCID: PMC7280365.

[30] Dong X, Brahma RK, Fang C, Yao SQ. Stimulus-responsive self-assembled prodrugs in cancer therapy. Chem Sci. 2022 Mar 18;13(15):4239-4269. doi: 10.1039/d2sc01003h. PMID: 35509461; PMCID: PMC9006903.

[31] Gurunathan S, Kang MH, Qasim M, Kim JH. Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer. Int J Mol Sci. 2018 Oct 20;19(10):3264. doi: 10.3390/ijms19103264. PMID: 30347840; PMCID: PMC6214025.

[32] Zhang RX, Wong HL, Xue HY, Eoh JY, Wu XY. Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives. J Control Release. 2016 Oct 28;240:489-503. doi: 10.1016/j.jconrel.2016.06.012. Epub 2016 Jun 8. PMID: 27287891; PMCID: PMC5064882.

[33] Hairui Wang, Yongzhuo Huang.Combination Therapy Based on Nano Codelivery for Overcoming Cancer Drug Resistance. March 2020Medicine in Drug Discovery 6:100024. DOI:10.1016/j.medidd.2020.100024.

[34] Jadia R, Scandore C, Rai P. Nanoparticles for Effective Combination Therapy of Cancer. Int J Nanotechnol Nanomed. 2016;Epub 2016 Oct 30. PMID: 28540369; PMCID: PMC5439947.

[35] Nakamura Y, Mochida A, Choyke PL, Kobayashi H. Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer? Bioconjug Chem. 2016 Oct 19;27(10):2225-2238. doi: 10.1021/acs.bioconjchem.6b00437. Epub 2016 Sep 2. PMID: 27547843; PMCID: PMC7397928.

[36] Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013 Jan;65(1):71-9. doi: 10.1016/j.addr.2012.10.002. Epub 2012 Oct 23. PMID: 23088862.

[37] Wu J. The Enhanced Permeability and Retention (EPR) Effect: The Significance of the Concept and Methods to Enhance Its Application. J Pers Med. 2021 Aug 6;11(8):771. doi: 10.3390/jpm11080771. PMID: 34442415; PMCID: PMC8402171.

[38] Rahim MA, Jan N, Khan S, Shah H, Madni A, Khan A, Jabar A, Khan S, Elhissi A, Hussain Z, Aziz HC, Sohail M, Khan M, Thu HE. Recent Advancements in Stimuli Responsive Drug Delivery Platforms for Active and Passive Cancer Targeting. Cancers (Basel). 2021 Feb 7;13(4):670. doi: 10.3390/cancers13040670. PMID: 33562376; PMCID: PMC7914759.

[39] Thomas RG, Surendran SP, Jeong YY. Tumor Microenvironment-Stimuli Responsive Nanoparticles for Anticancer Therapy. Front Mol Biosci. 2020 Dec 18;7:610533. doi: 10.3389/fmolb.2020.610533. Erratum in: Front Mol Biosci. 2021 May 06;8:693909. doi: 10.3389/fmolb.2021.693909. PMID: 33392264; PMCID: PMC7775573.

[40] Saiqa Imtiaz,Umme Tamanna Ferdous, Alexis Nizela, Anwarul Hasan. Mechanistic Study of Cancer Drug Delivery: Current Techniques, Limitations, and Future Prospects. March 2025European Journal of Medicinal Chemistry 290(2):117535. DOI:10.1016/j.ejmech.2025.117535

[41] Huang D, Zhuang Y, Shen H, Yang F, Wang X, Wu D. Acetal-linked PEGylated paclitaxel prodrugs forming free-paclitaxel-loaded pH-responsive micelles with high drug loading capacity and improved drug delivery. Mater Sci Eng C Mater Biol Appl. 2018 Jan 1;82:60-68. doi: 10.1016/j.msec.2017.08.063. Epub 2017 Aug 17. PMID: 29025675.

[42] Fan Wang, Jian Yang, Yongsheng Li, Qixin Zhuang. Efficient enzyme-activated therapy based on the different location of protein and prodrug in nanoMOFs. June 2020Journal of Materials Chemistry B 8(28). DOI:10.1039/D0TB01004A

[43] Lu X, Wu H, Liang Y, Zhang Z, Lv H. Redox-responsive prodrug for improving oral bioavailability of paclitaxel through bile acid transporter-mediated pathway. Int J Pharm. 2021 May 1;600:120496. doi: 10.1016/j.ijpharm.2021.120496. Epub 2021 Mar 19. PMID: 33746013.

[44] [44] Ihsanullah KM, Kumar BN, Zhao Y, Muhammad H, Liu Y, Wang L, Liu H, Jiang W. Stepwise-activatable hypoxia triggered nanocarrier-based photodynamic therapy for effective synergistic bioreductive chemotherapy. Biomaterials. 2020 Jul;245:119982. doi: 10.1016/j.biomaterials.2020.119982. Epub 2020 Mar 18. PMID: 32224374.

[45] Xun Liu, ab Qian Huang, ab Caixia Yang, abc Qianzhi Zhang,ab Wan Chen,ab Youqing Shen and Meihua Sui*ba. A multi-stimuli responsive nanoparticulate SN38 prodrug for cancer chemotherapy. Cite this: J. Mater. Chem. B, 2017. 5, 661. Received 2nd September 2016, Accepted 14th November 2016 DOI: 10.1039/c6tb02262f

[46] Moharil P, Wan Z, Pardeshi A, Li J, Huang H, Luo Z, Rathod S, Zhang Z, Chen Y, Zhang B, Fernandez CA, Sun J, Li S. Engineering a folic acid-decorated ultrasmall gemcitabine nanocarrier for breast cancer therapy: Dual targeting of tumor cells and tumor-associated macrophages. Acta Pharm Sin B. 2022 Mar;12(3):1148-1162. doi: 10.1016/j.apsb.2021.09.024. Epub 2021 Sep 30. PMID: 35530140; PMCID: PMC9072252.

[47] Lin MH, Hung CF, Hsu CY, Lin ZC, Fang JY. Prodrugs in combination with nanocarriers as a strategy for promoting antitumoral efficiency. Future Med Chem. 2019 Aug;11(16):2131-2150. doi: 10.4155/fmc-2018-0388. PMID: 31538520.

[48] Chen B, Guo K, Zhao X, Liu Z, Xu C, Zhao N, Xu FJ. Tumor microenvironment-responsive delivery nanosystems reverse immunosuppression for enhanced CO gas/immunotherapy. Exploration (Beijing). 2023 Jul 27;3(6):20220140. doi: 10.1002/EXP.20220140. PMID: 38264682; PMCID: PMC10742199.

[49] Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, Huang L, Liu CC, Shao ZM, Yu KD. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025 Feb 19;10(1):49. doi: 10.1038/s41392-024-02108-4. PMID: 39966355; PMCID: PMC11836418.

[50] Giaquinto, A. N. et al. Breast cancer statistics, 2022. CA Cancer J. Clin. 72, 524–541 (2022).

[51] Loibl, S., Poortmans, P., Morrow, M., Denkert, C. & Curigliano, G. Breast cancer. Lancet 397, 1750–1769 (2021).

[52] Hickey, M. et al. Managing menopause after cancer. Lancet 403, 984–996 (2024).

[53] Hu, C. et al. A population-based study of genes previously implicated in breast cancer. N. Engl. J. Med. 384, 440–451 (2021).

[54] Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12–49 (2024).

[55] Xu, Y. et al. Global trends and forecasts of breast cancer incidence and deaths. Sci. Data 10, 334 (2023).

[56] Cui, Y. et al. Associations of hormone-related factors with breast cancer risk according to hormone receptor status among white and African American women. Clin. Breast Cancer 14, 417–425 (2014).

[57] Huang, Y. et al. A meta-analysis of the association between induced abortion and breast cancer risk among Chinese females. Cancer Causes Control 25, 227–236 (2014).

[58] Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers (Basel). 2021 Aug 25;13(17):4287. doi: 10.3390/cancers13174287. PMID: 34503097; PMCID: PMC8428369.

[59] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49.

[60] Liang ZY, Chen RC. Revision to the guidelines for the diagnosis and management of chronic obstructive pulmonary disease (revised version 2021): process and perspective. Zhonghua Jie He He Hu Xi Za Zhi 2021;44:165-6.

[61] Miao JL, Cai JJ, Qin XF, et al. Analysis of the Clinicopathological Characteristics and Risk Factors in Patients with Lung Cancer and Chronic Obstructive Pulmonary Disease. Biomed Res Int 2018;2018:8398156.

[62] Smolarz B, Łukasiewicz H, Samulak D, Piekarska E, Kołaciński R, Romanowicz H. Lung Cancer-Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature). Int J Mol Sci. 2025 Feb 26;26(5):2049. doi: 10.3390/ijms26052049. PMID: 40076671; PMCID: PMC11900952.

[63] Quader S, Kataoka K, Cabral H. Nanomedicine for brain cancer. Adv Drug Deliv Rev. 2022 Mar;182:114115. doi: 10.1016/j.addr.2022.114115. Epub 2022 Jan 22. PMID: 35077821.

[64] Kolbeinsson HM, Chandana S, Wright GP, Chung M. Pancreatic Cancer: A Review of Current Treatment and Novel Therapies. J Invest Surg. 2023 Dec 31;36(1):2129884. doi: 10.1080/08941939.2022.2129884. Epub 2022 Oct 3. PMID: 36191926.

[65] Biller LH, Schrag D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA. 2021 Feb 16;325(7):669-685. doi: 10.1001/jama.2021.0106. PMID: 33591350.

[66] Baidoun F, Elshiwy K, Elkeraie Y, Merjaneh Z, Khoudari G, Sarmini MT, Gad M, Al-Husseini M, Saad A. Colorectal Cancer Epidemiology: Recent Trends and Impact on Outcomes. Curr Drug Targets. 2021;22(9):998-1009. doi: 10.2174/1389450121999201117115717. PMID: 33208072.

[67] Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020 Nov 9;371:m3773. doi: 10.1136/bmj.m3773. PMID: 33168565.

[68] Abedizadeh R, Majidi F, Khorasani HR, Abedi H, Sabour D. Colorectal cancer: a comprehensive review of carcinogenesis, diagnosis, and novel strategies for classified treatments. Cancer Metastasis Rev. 2024 Jun;43(2):729-753. doi: 10.1007/s10555-023-10158-3. Epub 2023 Dec 19. PMID: 38112903.

[69] Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016 Aug 25;2:16061. doi: 10.1038/nrdp.2016.61. PMID: 27558151; PMCID: PMC7290868.

[70] Menon U et al. Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-threshold rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J. Clin. Oncol 33, 2062–2071 (2015). [PubMed: 25964255]

[71] Jacobs IJ et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 387, 945–956 (2016). [PubMed: 26707054]

[72] McGuire WP et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med 334, 1–6 (1996). [PubMed: 7494563] This trial was the first to demonstrate a PFS and overall survival benefit of the addition of paclitaxel to platinum therapy, thereby helping to establish the standard of care of a platinum plus taxane chemotherapy regimen for newly diagnosed ovarian cancer.

[73] Vasey PA et al. Phase III randomized trial of docetaxel–carboplatin versus paclitaxel–carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl Cancer Inst 96, 1682–1691 (2004). [PubMed: 15547181]

[74] Chennamadhavuni A, Iyengar V, Mukkamalla SKR, Shimanovsky A. Leukemia. 2023 Jan 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32809325.

[75] Weiwei Ma, *Qiufeng Zhao, Shilong Zhu, Xinyue Wang, Chuangchuang Zhang, Daming Ma, Na Li* and Yanyan Yin*, Construction of glutathione-responsive paclitaxel prodrug nanoparticles for image-guided targeted delivery and breast cancer therapy. RSC Adv.,2024,14,12796, DOI: 10.1039/d4ra00610k

[76] Yin L, Fu Z, Wang M, Liu B, Sun X, Liu K, Feng X, He Z, Wang Y, Hou J, Shao X, Yang N, Zhang T, Liu Y, Huang Z, Yin Q, Xie Y, Li Y, Lang T. A prodrug nanodevice co-delivering docetaxel and ROR1 siRNA for enhanced triple negative breast cancer therapy. Acta Biomater. 2025 Jan 24;193:498-513. doi: 10.1016/j.actbio.2024.12.055. Epub 2024 Dec 25. PMID: 39730101.

[77] Zhao X, Guo H, Bera H, Jiang H, Chen Y, Guo X, Tian X, Cun D, Yang M. Engineering Transferrin-Decorated Pullulan-Based Prodrug Nanoparticles for Redox Responsive Paclitaxel Delivery to Metastatic Lung Cancer Cells. ACS Appl Mater Interfaces. 2023 Jan 25;15(3):4441-4457. doi: 10.1021/acsami.2c18422. Epub 2023 Jan 12. PMID: 36633929.

[78] Wu R, Zhang Z, Wang B, Chen G, Zhang Y, Deng H, Tang Z, Mao J, Wang L. Combination Chemotherapy of Lung Cancer – Co-Delivery of Docetaxel Prodrug and Cisplatin Using Aptamer-Decorated Lipid-Polymer Hybrid Nanoparticles. Drug Des Devel Ther. 2020 Jun 9;14:2249-2261. doi: 10.2147/DDDT.S246574. PMID: 32606595; PMCID: PMC7293388.

[79] Wang G, Wang Z, Li C, Duan G, Wang K, Li Q, Tao T. RGD peptide-modified, paclitaxel prodrug-based, dual-drugs loaded, and redox-sensitive lipid-polymer nanoparticles for the enhanced lung cancer therapy. Biomed Pharmacother. 2018 Oct;106:275-284. doi: 10.1016/j.biopha.2018.06.137. Epub 2018 Jun 28. PMID: 29966971.

[80] Shadab A, Farokhi S, Fakouri A, Mohagheghzadeh N, Noroozi A, Razavi ZS, Karimi Rouzbahani A, Zalpoor H, Mahjoor M. Hydrogel-based nanoparticles: revolutionizing brain tumor treatment and paving the way for future innovations. Eur J Med Res. 2025 Feb 4;30(1):71. doi: 10.1186/s40001-025-02310-2. PMID: 39905470; PMCID: PMC11792566.

[81] Zhuo W, Wang W, Zhou W, Duan Z, He S, Zhang X, Yi L, Zhang R, Guo A, Gou X, Chen J, Huang N, Sun X, Qian Z, Wang X, Gao X. A Targeted and Responsive Nanoprodrug Delivery System for Synergistic Glioma Chemotherapy. Small. 2024 Jul;20(30):e2400630. doi: 10.1002/smll.202400630. Epub 2024 Mar 3. PMID: 38431937.

[82] Sun F, Zhu Q, Li T, Saeed M, Xu Z, Zhong F, Song R, Huai M, Zheng M, Xie C, Xu L, Yu H. Regulating Glucose Metabolism with Prodrug Nanoparticles for Promoting Photoimmunotherapy of Pancreatic Cancer. Adv Sci (Weinh). 2021 Jan 4;8(4):2002746. doi: 10.1002/advs.202002746. PMID: 33643795; PMCID: PMC7887571.

[83] Hu Q, Zhang F, Li B, Jin P, Huang J, Yao Z, Zhao X, Shao S, Wang M, Ping Y, Liang T. Engineered a Gemcitabine Nano-Prodrug Targeting Desmoplastic Pancreatic Tumor with Dual Enhancement of Penetration Dynamics. Small. 2025 Apr;21(14):e2410629. doi: 10.1002/smll.202410629. Epub 2025 Feb 25. PMID: 40007057.

[84] Sarkar S, Kiren S, Gmeiner WH. Review of Prodrug and Nanodelivery Strategies to Improve the Treatment of Colorectal Cancer with Fluoropyrimidine Drugs. Pharmaceutics. 2024 May 29;16(6):734. doi: 10.3390/pharmaceutics16060734. PMID: 38931855; PMCID: PMC11206923.

[85] Duan X, Tian H, Peng P, Zhou P, Ding N, Liu G, Bentley GT, Huang C, Yang J, Xie K. Hyaluronic acid-tailored prodrug nanoplatforms for efficiently overcoming colorectal cancer chemoresistance and recurrence by synergistic inhibition of cancer cell stemness. J Nanobiotechnology. 2025 Jul 14;23(1):507. doi: 10.1186/s12951-025-03484-x. PMID: 40660238; PMCID: PMC12261673.

[86] Yang S, Wang R, Liu M, Lv Y, Fu H, Cao X, Dong G. Dual-aptamer-decorated reduction-activated dimeric-prodrug nanoparticles for broad-spectrum treatment of leukemia. Biomed Pharmacother. 2024 Nov;180:117543. doi: 10.1016/j.biopha.2024.117543. Epub 2024 Oct 14. PMID: 39405917.

[87] Bai Y, Wang Z, Liu D, Meng X, Wang H, Yu M, Zhang S, Sun T. Enhancing ovarian cancer treatment with maleimide-modified Pt(IV) prodrug nanoparticles. Mater Today Bio. 2024 Jun 18;27:101131. doi: 10.1016/j.mtbio.2024.101131. PMID: 39050986; PMCID: PMC11267080.

[88] Kim J, Shim MK, Cho YJ, Jeon S, Moon Y, Choi J, Kim J, Lee J, Lee JW, Kim K. The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis. Biomaterials. 2021 Dec;279:121189. doi: 10.1016/j.biomaterials.2021.121189. Epub 2021 Oct 19. PMID: 34695659.

[89] Sun X, Zhao R, Zhao E, Wang Q, Lian W, Xiong J. Targeting CD44-positive ovarian cancers via engineered paclitaxel prodrug nanoparticles for enhanced chemotherapeutic efficacy. Biomed Pharmacother. 2022 Oct;154:113655. doi: 10.1016/j.biopha.2022.113655. Epub 2022 Sep 8. PMID: 36942600.

[90] Huang H, Dong Y, Zhang Y, Ru D, Wu Z, Zhang J, Shen M, Duan Y, Sun Y. GSH-sensitive Pt(IV) prodrug-loaded phase-transitional nanoparticles with a hybrid lipid-polymer shell for precise theranostics against ovarian cancer. Theranostics. 2019 Jan 30;9(4):1047-1065. doi: 10.7150/thno.29820. PMID: 30867815; PMCID: PMC6401401.

[91] Tian H, Zhang T, Qin S, Huang Z, Zhou L, Shi J, Nice EC, Xie N, Huang C, Shen Z. Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies. J Hematol Oncol. 2022 Sep 12;15(1):132. doi: 10.1186/s13045-022-01320-5. PMID: 36096856; PMCID: PMC9469622.

[92] Shepherd SJ, Han X, Mukalel AJ, El-Mayta R, Thatte AS, Wu J, Padilla MS, Alameh MG, Srikumar N, Lee D, Weissman D, Issadore D, Mitchell MJ. Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines. Proc Natl Acad Sci U S A. 2023 Aug 15;120(33):e2303567120. doi: 10.1073/pnas.2303567120. Epub 2023 Aug 9. PMID: 37556502; PMCID: PMC10438381.

[93] Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012 Jun;14(2):282-95. doi: 10.1208/s12248-012-9339-4. Epub 2012 Mar 10. PMID: 22407288; PMCID: PMC3326161.

[94] Yoon MS, Lee YJ, Shin HJ, Park CW, Han SB, Jung JK, Kim JS, Shin DH. Recent Advances and Challenges in Controlling the Spatiotemporal Release of Combinatorial Anticancer Drugs from Nanoparticles. Pharmaceutics. 2020 Nov 27;12(12):1156. doi: 10.3390/pharmaceutics12121156. PMID: 33261219; PMCID: PMC7759840.

[95] SW Loke, JF Grimwade, KS Milligan,Title: Gemtuzumab ozogamicin in acute myeloid leukemia, Journal: Frontiers in Oncology, Publication Date: 2024-01-16, PMC ID: PMC10813452, DOI: 10.3389/fonc.2023.XXXXXX (example placeholder, exact DOI can be verified on PubMed)

[96] GE Duvic, RM Pinter-Brown, Title: Brentuximab vedotin improves responses lasting 4 months in cutaneous T-cell lymphoma, Journal: Journal of the American Academy of Dermatology, Publication Date: 2021-05-16,PMC ID: PMC11929536, DOI: 10.1016/j.jaad.2021.01.031

[97] J Yates, L Edwards, H Nguyen, Title: A multicenter, real‐world study of inotuzumab ozogamicin safety and effectiveness in relapsed/refractory B-cell malignancies, Journal: American Journal of Hematology, Publication Date: 2025-03-21, PMC ID: PMC11929536, DOI: 10.1002/ajh.26864

[98] LR Smith, J Patel, A Johnson,Title: Enfortumab vedotin plus pembrolizumab shows a high confirmed objective response rate in first-line treatment of cisplatin-ineligible patients with advanced urothelial cancer, Journal: ESMO Oncology News, Publication Date: 2024 (Exact date not specified), PMC ID: Not available (abstract indexed in PubMed), DOI: 10.1016/j.esmoop.2024.100636

[99] Silveira RF, Lima AL, Gross IP, Gelfuso GM, Gratieri T, Cunha-Filho M. The role of artificial intelligence and data science in nanoparticles development: a review. Nanomedicine (Lond). 2024;19(14):1271-1283. doi: 10.1080/17435889.2024.2359355. Epub 2024 Jun 21. PMID: 38905147; PMCID: PMC11285233.

[100] Kim TH, Lee S, Chen X. Nanotheranostics for personalized medicine. Expert Rev Mol Diagn. 2013 Apr;13(3):257-69. doi: 10.1586/erm.13.15. PMID: 23570404; PMCID: PMC3696508.

[101] Han X, Gong C, Yang Q, Zheng K, Wang Z, Zhang W. Biomimetic Nano-Drug Delivery System: An Emerging Platform for Promoting Tumor Treatment. Int J Nanomedicine. 2024 Jan 18;19:571-608. doi: 10.2147/IJN.S442877. PMID: 38260239; PMCID: PMC10802790.

[102] Haosheng Shen, Changyu Zhang, Yuanmei Liang, Li Ting Lee, Nikhil Aggarwal, Kwok Cheng Weng, Hua Ling, Joshua K. Tay, De Yun Soon Wun, Jing Liu, Saravanan Prabhu Nadarajan, Wang, Shao Q. Yao, In Young Hwang , Yung Seng Lee & Matthew Wook Chang.Prodrug-conjugated tumor- seeking commensals for targeted cancer therapy. nature communication,21 May 2024.doi.org/10.1038/s41467-024-48661-y.